Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP.
about
Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes.Cross-camera comparison of ROI-based semi-quantitative ¹²³I-IBZM SPECT data in healthy volunteers using an anthropomorphic phantom for calibration.Vascular parkinsonism--characteristics, pathogenesis and treatment.Motor deficits and altered striatal gene expression in aphakia (ak) mice.Metabolomic profiling in LRRK2-related Parkinson's diseaseImaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts.SPECT molecular imaging in Parkinson's diseaseThe search for biomarkers in Parkinson's disease: a critical review.Proposed neuroimaging criteria for the diagnosis of multiple system atrophy.The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration.Diagnosis and differential diagnosis of MSA: boundary issues.Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease.Pre- and postsynaptic dopamine SPECT in idiopathic Parkinsonian diseases: a follow-up study.Clinical correlates of similar pathologies in parkinsonian syndromes.Abnormalities of dopaminergic neurotransmission in SCA2: a combined 123I-betaCIT and 123I-IBZM SPECT study.Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program.Potential clinical utility of multiple system atrophy biomarkers.Neurotransmitter deficits from frontotemporal lobar degeneration.Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]β-CIT SPECT.F-18 FP-CIT PET in Multiple System Atrophy of the Cerebellar Type: Additional Role in Treatment.A novel computer-assisted image analysis of [123I]β-CIT SPECT images improves the diagnostic accuracy of parkinsonian disorders.Generalized five-dimensional dynamic and spectral factor analysis.Topography of putaminal degeneration in multiple system atrophy: a diffusion magnetic resonance study.Brain perfusion differences in parkinsonian disorders.Evaluation of (99m)Tc-TRODAT-1 SPECT in the diagnosis of Parkinson's disease versus other progressive movement disorders.Neuroimaging in Dementia.Different loss of dopamine transporter according to subtype of multiple system atrophy.Correlation between neuromelanin-sensitive MR imaging and (123)I-FP-CIT SPECT in patients with parkinsonism.[Differential diagnostics of Parkinson's disease with nuclear medicine procedures].Combined DaT imaging and olfactory testing for differentiating parkinsonian disorders.Can imaging separate multiple system atrophy from Parkinson's disease?
P2860
Q30480599-FD3FE776-E118-4680-956E-13C9470982A0Q30596793-68A7F911-46A5-4B51-A72D-14FF54C8F9ACQ30940108-9DC7DF13-ECB1-42AE-B70C-346C58F0C140Q33303267-4D762717-E1E0-467A-9ECA-E2845859EA70Q33511761-EC4CD681-2A17-4451-B1F7-6897C51D5A9EQ34554452-5CA45C5C-8F53-4A94-9CA1-62C9F6D9303DQ35875725-0E18AB74-B2F5-4CF0-8A31-FB60E46A6707Q37352054-C301D81C-9458-4022-B1AF-4A6D678C9665Q37420656-EC98D899-A83F-4B3B-A7FF-10474BE33506Q37910636-52A04537-70C1-4C53-947F-B4343777530DQ38348584-F6AA4A6C-6AD9-4BD9-91C4-D98811C0A0E7Q39303669-5287EBB5-41DE-4A88-8800-0D23A4D1ACDDQ40202363-58448D6C-259B-45A7-A827-0B167D615B15Q41969925-54FEFC5A-22E5-46CA-9815-1F4AE33B1FE5Q42482935-80000EFC-AAE6-4A09-9D27-7A0414730192Q45076635-9AE8FC4B-4353-4617-995F-5997E78B9EEAQ47338262-AED34372-1311-4224-BA31-5CF2F4A1C4A0Q47663712-B4AB1A94-2D09-42E1-A080-E80F93020606Q47837913-8246B4EE-929C-46DB-AB8C-6A7E139CBD1FQ48174151-99767A06-91F2-40FE-AABD-74EE95BFA64AQ48247496-0CD5D794-43D8-4C68-B683-0085AC450852Q48303226-EA002204-B48F-4F17-9114-C96CEEF1D838Q48542906-4AEF4203-89E2-4E52-B1EB-432FDE68770FQ48617950-D1C4A3F8-9EE8-4C1C-BEF2-BA1DED6AB3B6Q48955604-958B017A-3A2E-4B56-BF72-9C192A8D3845Q50243794-A9404ABD-10AD-4052-98D8-08A4772A1184Q51800676-0F333D5D-FC1C-42D0-A5F5-14561ABF06C7Q52149073-DCD47994-0EE6-4F91-96EE-AE38F9984C23Q52985613-F25367ED-E64A-4A14-9959-A7352FC3C01DQ53066302-2A598213-5442-433C-9E62-75DCF03CA848Q53463753-69C9EBDD-B0F0-415D-B561-8A81FE6E256AQ54336783-F0EEE38A-D030-43F8-B7FB-0E9BD8261F0B
P2860
Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Combination of dopamine transp ...... valuation of PD, MSA, and PSP.
@en
Combination of dopamine transp ...... valuation of PD, MSA, and PSP.
@nl
type
label
Combination of dopamine transp ...... valuation of PD, MSA, and PSP.
@en
Combination of dopamine transp ...... valuation of PD, MSA, and PSP.
@nl
prefLabel
Combination of dopamine transp ...... valuation of PD, MSA, and PSP.
@en
Combination of dopamine transp ...... valuation of PD, MSA, and PSP.
@nl
P2093
P2860
P356
P1433
P1476
Combination of dopamine transp ...... valuation of PD, MSA, and PSP.
@en
P2093
Douglas Vines
James R Ballinger
Masanori Ichise
Sean S Erami
Tatsuro Tatschida
P2860
P304
P356
10.1002/MDS.10042
P407
P577
2002-03-01T00:00:00Z